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Overweight and obesity trends are rapidly rising in 
developed countries such as Australia, Canada, USA, 
and the UK, with over 50% of the population catego-
rized as overweight/obese in 2004 [1]. This rate is 
predicted to rise to over 60% by the end of this decade, 
leading to a significant comorbidity in the majority of 
our population. Obesity has been established as a prog-
nostic factor for the development of colorectal cancer 
(CRC), accounting for up to 35% of CRC cases, and 
is associated with a higher risk of recurrence and colon 
cancer- specific mortality in the adjuvant setting 
[2–6].
Preclinical work suggests a link between insulin resist-
ance, related to obesity, and colorectal carcinogenesis [6]. 
Factors that are raised in obesity, such as blood insulin 
levels, insulin- like growth factor (IGF) 1, leptin, interleukin 
6, and tumor necrosis factor- alpha (TNF- α) are associated 
with activation of intracellular signaling pathways, such 
as the PI3kinase or mitogen-activated protein kinases 
(MAPK) pathway [7, 8]. These pathways are also targeted 
by epidermal growth factor inhibitors (EGFR), for example, 
cetuximab and crosstalk with the above- mentioned 
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Abstract
Although a raised body mass index (BMI) is associated with increased risk of 
colorectal cancer (CRC) and recurrence after adjuvant treatment, data in the 
metastatic setting is limited. We compared overall survival (OS) across BMI 
groups for metastatic CRC, and specifically examined the effect of BMI within 
the group of patients treated with targeted therapies (TT). Retrospective data 
were obtained from the South Australian Registry for mCRC from February 
2006 to October 2012. The BMI at first treatment was grouped as underweight 
<18.5 kg/m2, Normal = 18.5 to <25 kg/m2, Overweight = 25 to <30 kg/m2, 
Obese I = 30 to <35 kg/m2, Obese II ≥35 kg/m2. Of 1174 patients, 42 were 
underweight, 462 overweight, 175 Obese I, and 77 Obese II. The OS was shorter 
for patients who were underweight and overweight compared to normal (OS 
13.7 and 22.3 vs. 24.1 months, respectively, hazard ratio [HR] 2.21 and 1.23). 
The adjusted median OS was longer for normal versus overweight or obese I 
patients receiving chemotherapy + targeted therapy (35.7 vs 25.1 or 22.8 months, 
HR 1.59 and 1.63, respectively) with no difference in OS for chemotherapy 
alone. On breakdown by type of targeted therapy, overweight and obese I patients 
had a poorer outcome with Bevacizumab. The BMI is predictive of a poorer 
outcome for underweight and overweight patients in the whole population. Of 
those receiving chemotherapy and targeted therapy, BMI is an independent 
 predictor for OS for overweight and obese I patients, specifically for those treated 
with Bevacizumab. Patients who are overweight or obese (group I) may be a 
target group for lifestyle and nutrition advice to improve OS with TT.
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proinflammatory pathways may lead to resistance to EGFR 
inhibitors [9]. Furthermore, elevated leptin levels are cor-
related with production of vascular endothelial growth 
factor (VEGF) [10], leading to angiogenesis, which may 
lead to resistance to VEGF- targeted drugs, such as beva-
cizumab in obesity- associated cases. From this data, we 
hypothesized that adiposity, and a raised BMI, may be 
negatively associated with survival in patients with CRC, 
especially those treated with targeted therapies (TT) such 
as bevacizumab and cetuximab, versus those receiving 
chemotherapy alone.
Few studies have demonstrated evidence pertaining to 
the effect of obesity on clinical outcome in patients with 
metastatic colorectal cancer (mCRC), and results are con-
flicting. Two retrospective trials have reported on the 
association of body mass index (BMI) with overall survival 
(OS) and/or time to progression (TTP) in patients treated 
with bevacizumab [11, 12]. One study found an increase 
in BMI to be associated with a better OS, for those  patients 
treated with chemotherapy, but no significant association 
in a group treated with chemotherapy and bevacizumab 
[11]. However, Guiu et al. showed that high BMI and 
visceral fat area (VFA) were associated with reduced re-
sponse rates, disease- free survival and OS in patients treated 
with bevacizumab and chemotherapy, but there was no 
significant association between these factors and outcome 
in patients treated with chemotherapy [12]. The CO.17 
study examined the association between various factors, 
including BMI, comorbidity and age, and OS in cetuximab- 
treated patients with mCRC and found no difference in 
OS according to BMI [13]. On the other hand, studies 
have reported either no association between BMI and OS, 
in patients with mCRC undergoing hepatectomy [14], or 
a negative effect only in men with CRC [15]. Further 
work is necessary in this field to elucidate the effect, if 
any, of BMI upon outcome for mCRC  patients. Our aim 
was to compare OS across BMI groups for mCRC, and 
specifically examine the effect within the group of patients 
treated with TT. In particular, the primary objective of 
the study was to examine whether BMI was prognostic 
of OS, defined as the interval from the first diagnosis of 
mCRC to death or last follow up. The  secondary objec-
tive was to examine the association of BMI with OS for 
the subgroup of patients receiving therapies targeted to 
the EGFR or VEGF, according to the biological 
rationale discussed above.
Materials and Methods
Retrospective data were collected from the South Australian 
Clinical Registry for mCRC [16] which is a state- wide 
population- based database including data from all patients 
diagnosed with mCRC from February 1, 2006. Data on 
patient details such as age, sex, demographics, tumor 
characteristics, including site, histopathological subtype, 
differentiation, and metastatic site, investigations, treat-
ment, such as surgical procedures, chemotherapy, targeted 
therapy, radiotherapy, radiofrequency ablation and selective 
internal radiation therapy and outcomes are included. 
Patient selection is based upon the relevant International 
Classification of Diseases codes from inpatient and out-
patient encounters, histopathology reports, clinical noti-
fication, attendance at multidisciplinary meetings and death 
audits. Cancer- specific mortality was obtained for each 
patient through medical record review and electronic link-
age with the State death records.
Baseline BMI was calculated as weight in kilograms 
divided by height, in metres squared, as recorded at first 
diagnosis of mCRC, prior to treatment with chemotherapy. 
BMI groups for analysis were based upon the World 
Health Organisation (WHO) criteria [17] as below:
Underweight = <18.5 kg/m2, normal weight = 18.5 to 
<25 kg/m2, Overweight = 25 to <30 kg/m2, Obese I = 30 
to <35 kg/m2, Obese II/III = 35 kg/m2 or greater.
Overall survival analysis was initially carried out for 
the whole population, and then within subgroups accord-
ing to treatment type. Patients treated with chemotherapy 
alone were classified as the chemotherapy group and 
 patients who received targeted treatments +/− chemo-
therapy at any point in the treatment for metastatic disease 
were classed as the chemotherapy and antibody treatment 
group. The underweight group was excluded from analysis 
by treatment type due to the extremely small numbers 
in the chemotherapy and antibody treatment group, which 
did not allow for multivariate regression analysis for OS. 
Data regarding progression free survival or change in BMI 
over the course of treatment was not robustly available 
for all patients and therefore was not analyzed.
All analyses were performed using STATA software 
(Version 11: Stata Corp., TX).
Cox proportional hazards models were fitted to evaluate 
the cumulative survival probabilities among the BMI 
groups. The time to event was defined as the interval 
from the first diagnosis of mCRC to death or last follow-
 up, which comes first. The census date was 31 October 
2012.
Multivariate Cox PH regression analysis was used to 
adjust for confounders such as gender, age, number of 
metastatic sites, metachronous versus synchronous pres-
entation (whether patients presented with stage I–III disease 
and subsequently developed metastases, versus metastatic 
disease at presentation), number of lines of chemotherapy, 
and the number of lines of TT received. A PH assump-
tion was tested and confirmed to satisfy assumption. OS 
were evaluated by Kaplan–Meier survival curves and groups 
were compared by log- rank test. Analysis of variance 
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(ANOVA) or chi- squared tests, including post hoc cor-
rections where necessary, were used to compare patient 
demographic groups. Although the number of patients is 
unequal for BMI groups, this lack of balance does not 
present serious problems for one factor ANOVA [18, 19].
Results
Patient demographics
In total, 1174 patients were available for the calculation 
of BMI at first presentation of mCRC. BMI was only 
recorded on the database for patients who received 
chemotherapy. A further 285 patients were treated with 
chemotherapy but BMI records were not available in the 
notes.
Of the 1174 patients included in the study, 42 (3.6%) 
patients were underweight, 418 (35.6%) were of normal 
weight, 462 (39.4%), overweight, 175 (14.9%), obese (group 
1) and 77 (6.6%), obese (groups 2 and 3) with a BMI 
of over 35 kg/m2. Patient demographics for the all patients 
are displayed in Table 1. There were no significant dif-
ferences between BMI groups for the whole dataset in 
terms of age, number of metastatic sites, number of lines 
of chemotherapy or antibody therapy or by KRAS muta-
tion status. However, within the whole group, patients 
who were underweight were more likely to be female 
rather than male. A higher proportion of normal weight 
patients presented with synchronous metastasis (metastatic 
disease at first presentation) compared to the underweight, 
overweight or obese patient groups. Normal weight patients 
were more likely to receive chemotherapy alone compared 
to overweight patients who were more likely to receive 
chemotherapy and at least one line of targeted therapy 
(75.1% of normal weight patients received no lines of 
antibody treatment compared to 64.5% of overweight 
patients). No significant differences were detected between 
the obese patient groups compared to the normal under-
 or overweight groups.
Of all the patients analyzed above, 814 received chemo-
therapy alone compared to 360 patients who received 
chemotherapy and at least one line of targeted therapy, 
including bevacizumab, cetuximab, panitumumab, and/or 
regorafenib. Patient demographics for these two groups 
of patients, split by BMI are shown in Table 2, with the 
only significant difference in both groups being the stage 










Obese I  
(n = 175)
Obese II  
(n = 77)
Age (mean) 65.4 64.6 64.4 62.9 63.3 0.34
Sex (%)
 Female 59.5 37.7 32.91 39.7 46.2 <0.01
 Male 40.51 62.3 67.11 60.3 53.8
Group (%)
 Chemotherapy only 81.0 75.11 64.51 66.3 67.9 <0.01
Antibody tx 19.0 24.91 35.51 33.7 32.1
Stage at dx (%)
 Synchronous disease 61.9 77.81 64.3 60.6 57.7 <0.001
No. of met sites
 1 76.2 73.9 74.0 73.7 71.8 0.98
  >1 23.8 26.1 26.0 26.3 28.2
Chemo line (%)
 1 50.0 45.5 39.9 45.1 52.6 0.55
 2 31.0 30.1 30.8 31.4 23.1
 3 16.7 16.3 18.4 16.0 14.1
 4 2.4 6.2 7.2 6.3 9.0
 5+ – 1.9 3.7 1.1 1.3
Ab line (%)
 0 81.0 75.11 64.51 66.3 67.9 0.05
 1 16.7 17.51 27.91 25.7 25.6
 2 – 5.7 5.4 6.3 6.4
 3 2.4 1.7 2.2 1.7 –
KRAS mutation 4.8 10.8 12.3 12 7.7 0.93
Underweight, BMI < 18.5, Normal, BMI 18.5–24.9; Overweight, BMI 25.0–29.0; Obese I, BMI 30.0–34.9; Obese II, BMI ≥ 35; Percent of patients 
in each group by BMI category are shown. P- values are based on ANOVA for continuous data and Chi- square test for categories.
1Denotes a subset of BMI categories whose column proportions differ significantly from the other columns at the 0.5 level.
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of disease at presentation. Within both treatment groups, 
normal weight patients were more likely to present with 
synchronous disease compared to overweight or obese 
patients, as described for the whole patient group above. 
As only 8 patients in the underweight group received 
chemotherapy and antibody treatment, we could not carry 
out a multivariate analysis for this subgroup, and thus 
the underweight patients were excluded from this part of 
the study.
Types of TT used
The majority of patients received bevacizumab, either in 
the first or second line of treatment, with the mode fall-
ing in the group of patients receiving second line treat-
ment, as shown in Table 3. Significantly fewer patients 
received EGFR- TT, with the mode falling in the 4th line 
of treatment for both cetuximab and panitumumab. Within 
this group, cetuximab was the preferred option. Very few 
patients received regorafenib, usually within the context 
of a clinical study.
OS analysis
Multivariate analysis by cox regression modeling was 
carried out for the whole dataset and adjusted for age, 




Chemotherapy and antibody treatment
P- value

























Age (mean) 66.0 65.9 65.8 64.4 63.5 0.36 62.5 60.9 61.9 59.9 63.1 0.57
Sex (%)
 Female 58.81 36.1 33.21 44.0 47.2 0.01 62.5 42.7 32.3 31.0 44.0 0.16
 Male 41.21 63.9 66.81 56.0 52.8 37.5 57.3 67.7 69.0 56.0
Synchronous  
 disease (%)
61.8 77.71 65.9 56.0 58.5 0.001 62.5 77.91 61.6 69.5 56.0 0.05
No. of met sites (%)
 1 73.5 73.2 75.5 73.3 71.7 0.96 87.5 76.0 71.3 74.6 72.0 0.81
  >1 26.5 26.8 24.5 26.7 28.3 12.5 24.0 28.7 25.4 28.0
No of lines of chemo (%)
 1 55.9 51.3 45.1 54.3 66.0 0.38 25.0 27.9 30.5 27.1 24.0 0.74
 2 32.4 31.2 35.4 30.2 18.9 25.0 26.9 22.6 33.9 32.0
 3 8.8 12.4 14.1 11.2 7.5 50.0 27.9 26.2 25.4 28.0
 4 2.9 3.2 4.0 4.3 7.5 15.4 12.8 10.2 12.0
 5+ – 1.9 1.3 – – – 1.9 7.9 3.4 4.0
No. of lines of antibody (%)
 0 _ _ _ _ _ _ _ _ _ – 0.56
 1 – – – – – 87.5 70.2 78.7 76.3 80.0
 2 _ _ _ _ _ _ 23.1 15.2 18.6 20.0
 3 – – – – – 12.5 6.7 6.1 5.1 –
%pt KRAS  
 tested
5.9 22.9 20.8 20.7 11.3 0.08 75.0 45.2 49.4 49.2 60.0 0.41
Type of KRAS (%)
  KRAS wild  
 type
50.0 55.6 41.9 58.3 50.0 0.53 83.3 72.3 74.1 62.1 80.0 0.65
 KRAS mutant 50.0 44.4 58.1 41.7 50.0 16.7 27.7 25.9 37.9 20.0
P- values are based on ANOVA for continuous data and Chi- square test for categories.
1Denotes a subset of BMI categories whose column proportions differ significantly from the other columns at the 0.5 level.
Table 3. Number of patients receiving targeted agents by line of 
treatment.
1 st line 2nd line 3rd line 4th line
5th line and 
beyond
Bevacizumab 91 126 43 21 19
Cetuximab 5 21 30 41 32
Panitumumab 4 3 7 10 3
Regorafenib 1 0 4 0 1
None 251 202 268 280 297
Numbers in bold denote the mode for each group.
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sex, synchronous disease at presentation, number of 
metastatic sites, number of lines of chemotherapy, and 
number of lines of targeted treatment. This demonstrated 
a significant reduction in OS for patients in the under-
weight group of 13.7 months compared to 24.1 months 
for the normal weight group, with a hazard ratio (HR) 
of 2.21 (95% CI 1.53–3.19; P < 0.001) (Fig. 1B). 
Furthermore, there was a significant increase in the risk 
of death within the overweight group, HR 1.23(95% CI 
1.03–1.46, P = 0.02), with no significant differences in 
survival for the obese groups compared to the normal 
weight group. Independent predictors of survival included 
greater than one metastatic site (HR 1.50, 95% CI 1.27–1.77 
P < 0.001) and number of lines of chemotherapy treat-
ment, with the HRs reducing in proportion to the number 
of lines of chemotherapy tolerated (Fig. 1B). However, 
the HRs for number of lines of antibody used were not 
statistically significant.
Overall survival analysis for patients treated with chemo-
therapy alone demonstrated no difference in median OS 
by BMI. The underweight group was not included in this 
analysis due to the small numbers within subgroups, which 
did not allow for multivariate analysis. HRs for OS in 
this group were 1.08, 1.07, and 0.84 for the overweight, 
obese I, and obese II/III groups, respectively, when com-
pared with the normal group, with no significant P values 
(Table S1). Within this analysis, age, number of metastatic 
sites, and number of lines of chemotherapy were inde-
pendent predictors for survival, as expected. Comparison 
of median OS for patients receiving chemotherapy alone 
versus chemotherapy and TT, within each BMI group 
demonstrated a survival benefit for the addition of TT 
Figure 1. Kaplan–Meier survival curves (A) and multivariate Cox proportional hazard model (hazard ratio [HR] and and 95% CI) for overall survival by 
BMI for the whole population (B). Model was adjusted by potential confounders: age, sex, synchronous disease, >1 met site, number of lines of 
chemotherapy and number of lines of antibody.
A
B
Hazard ratio 95% CI P value Median OS
BMI group
Underweight 2.21 1.53-3.19 <0.001 13.7
Normal R (1.00) - - 24.1
Overweight 1.23 1.03-1.46 0.02 22.3
Obese I 1.20 0.94-1.51 0.14 21.9
Obese II 0.89 0.64-1.23 0.498 26.3
Age (>70) 1.00 0.996-1.01 0.50
Sex (Male) 0.87 0.74-1.02 0.08
Synchronous disease 1.16 0.98-1.36 0.08
> 1met site 1.50 1.27-1.77 <0.001
No of lines of 
chemotherapy
1 R (1.00)
2 0.72 0.60-0.86 <0.001
3 0.71 0.57-0.88 <0.01
4 0.61 0.46-0.82 <0.01
5+ 0.37 0.22-0.62 <0.001
No of lines of 
antibody
1 0.89 0.73-1.08 0.23
2 0.89 0.64-1.25 0.50
3 0.82 0.46-1.47 0.51
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in the normal group only (OS 21.0 vs. 35.7 months, HR 
0.66, P- value < 0.01) (Fig. 2).
Within the prespecified patient group receiving TT 
and chemotherapy, median OS was significantly longer 
for normal weight patients compared to overweight and 
obese I patients (35.7 months, vs. 25.1 and 22.8 months 
respectively), with HR of 1.59, P = 0.006, 1.63, and 
0.049, respectively, as shown in Table 4. Upon break-
down by type of TT, this difference was significant for 
patients receiving VEGF- targeted treatment but not for 
EGFR TTs, likely due to the small numbers in the latter 
group. Patients receiving both VEGF and EGFR- TT were 
 excluded from the analysis presented in Table 4. Median 
OS for overweight and obese I patients was half than 
Figure 2. Kaplan–Meier survival curves (A), and Cox proportional hazard model (hazard ratio [HR], 95% CI and median overall survival [OS]) for overall 





































1467© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
 
BMI and Overall Survival in Metastatic CRCG. S. Patel et al.
that seen for normal weight patients for those treated 
with VEGF- TT (17.5 months, and 16 months compared 
to 36.1 months, respectively, with HR of 2.08, P = 0.001, 
2.67, 0.004).
The results described for the group of patients receiving 
any TT retained significance on adjustment for age, sex, 
synchronous disease, number of metastatic sites, number 
of lines of chemotherapy, and TT, by multivariate analysis 
(Fig. 3B). Independent predictors of death included age 
of greater than 70, and synchronous disease at presenta-
tion. The number of lines of chemotherapy received, but 
not the number of lines of TT, was an independent pre-
dictor for survival. The Kaplan–Meier survival curves 
corresponding to this data are shown in Figure 3A.
The interactions of age with BMI and sex with BMI 
were not significant and were not included in the model 
of VEGFR TT, EGFR TT, and all TT for evaluating the 
cumulative survival probabilities among the BMI groups.
Discussion
Upon analysis of the entire patient group, irrespective 
of treatment, a poor OS for underweight patients was 
demonstrated with a median OS of 13.7 months com-
pared to 24.1 months, and a HR of 2.21. Patients in 
the overweight group also demonstrated a poorer OS 
compared to the normal group with a median OS of 
22.3 compared to 24.1 months, with a HR of 1.23. No 
significant difference was demonstrated between the 
normal and obese groups. These differences in OS are 
likely to be due to different pathologies in the two dif-
ferent BMI groups. An underweight BMI at presentation 
may in fact represent cachexia associated with aggressive 
metastatic disease, which may be related to a poor per-
formance status, thus preventing effective chemothera-
peutic treatment. Indeed patients within this group were 
the most likely to receive chemotherapy alone compared 
to chemotherapy plus TT, as demonstrated in Table 1. 
This finding is supported by a study carried out by 
Parsons et al. who investigated the association of body 
composition parameters and outcome for patients receiv-
ing hepatic arterial infusion chemotherapy for metastatic 
liver disease [20]. Sarcopenic patients demonstrated a 
poor OS of 103 days versus 312 days, but their results 
were not significant in a small patient population of 20 
sarcopenic patients. Van Vledder et al. demonstrated 
that sarcopenia was an independent predictor of worse- 
recurrence free survival and OS after surgery for colo-
rectal liver metastases (HR of 1.88, P < 0.01, 2.53, 0.001, 
 respectively) [21].
Conversely, overweight patients were also found to have 
a statistically significant reduction in OS compared to 
normal weight patients. However, this group was more 
likely to demonstrate good prognostic factors, such as 
metachronous disease at presentation and treatment with 
at least one line of TT compared to normal weight 
 patients. The reasons behind these discrepancies is not 
entirely clear but may be related. For instance, if over-
weight  patients had previously received adjuvant chemo-
therapy, they may be more likely to be offered antibody 
therapy in conjunction with chemotherapy compared to 
chemotherapy- naive patients. The overweight group would 
be expected to do as well as, if not better than the 
normal weight group in terms of OS, but this was not 
the case. We conclude that an overweight BMI may rep-
resent an independent, poor, prognostic indicator for 
Table 4. Multivariate Cox proportional hazard model (Hazard ratios [HR], 95% CI and overall survival [OS]) for BMI groups by type of targeted 
therapy.
Normal Overweight Obese I Obese II
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
OS OS OS OS
A11TT (N = 352) 1.00 1.59 (1.14–2.21) 1.63 (1.01–2.65) 1.11(0.60–2.06)
35.7 months 25.1 months 22.8 months 30.8 months
P = 0.006 P = 0.049 P = 0.740
N = 104 N = 164 N = 59 N = 25
VEGFR TT (N = 200) 1.00 2.08 (1.35–3.21) 2.67 (1.37–5.20) 0.81 (0.30–2.21)
36.1 months 17.5 months 16.0 months 63.5 months
P = 0.001 P = 0.004 P = 0.677
N = 63 N = 91 N = 35 N = 11
EGFR TT (N = 106) 1.00 1.33 (0.72–2.47) 0.95 (0.39–2.27) 1.90 (0.67–5.38)
40.8 months 30.3 months 41.6 months 31.8 months
P = 0.356 P = 0.900 P = 0.230
N = 27 N = 52 N = 17 N = 10
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survival in patients undergoing chemotherapy +/− TT 
for metastatic CRC.
On analysis by treatment type, the most significant 
finding is that BMI is an independent predictor for 
poorer outcome for patients in the overweight and obese 
I group for patients treated with chemotherapy and TT 
but not for patients treated with chemotherapy alone. 
The only significant difference in patient demographics 
by BMI for this group of patients was that normal 
weight patients were more likely to present with syn-
chronous metastases, which has been shown to be 
 associated with a poorer OS, compared to the overweight 
or obese groups. Although there is evidence that male 
gender is associated with an earlier occurrence of CRC 
[22], our interaction analysis discovered no effect for 
sex by BMI in this population. However, the numbers 
of patients treated with EGFR TT were small in this 
study.
Analysis by type of TT used demonstrates a worse 
 median OS for patients in the overweight and obese I 
group compared to the normal group for patients treated 
with VEGF inhibitors (i.e., Bevacizumab) but not with 
EGFR TT (Table 4). No significant differences were noted 
between OS for the obese II/III group and the normal 
Figure 3. Kaplan–Meier overall survival curves (A) and multivariate Cox proportional hazard model (Hazard ratio [HR] and and 95% CI) for overall 
survival by BMI for patients receiving any TT (B). Model was adjusted by potential confounders: age, sex, synchronous disease, >1 met site, number 
of lines of chemotherapy and number of lines of TT.
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group, which may be related to the small numbers within 
this group (n = 25). These findings support the prede-
termined biological hypothesis proposing resistance to 
anti- angiogenic therapy due to the potential inflammatory 
and proangiogenic properties associated with adipose tis-
sue. Interestingly, although adiposity is associated with 
IGFR activation, a proposed mechanism of resistance to 
EGFR TT, no difference in OS was found in between 
the BMI groups for patients treated with EGFR TT alone. 
However, total numbers within the EGFR TT group were 
small within our study.
Our results are in concordance with Guiu et al. who 
retrospectively demonstrated that a high VFA higher than 
the median is associated with a poorer response to 
VEGF- TT as well as shorter OS in patients treated with 
bevacizumab and chemotherapy in the first line treatment 
of metastatic CRC [12]. However, in their study, mul-
tivariate analysis did not confirm that a BMI of greater 
than 23.6 (median in their population) was predictive 
of response or prognostic of OS. Faruk Aykan et al. also 
report a similar effect, with a reduction in progression- 
free survival for patients with mCRC, treated with beva-
cizumab in a small (80 patients) retrospective series [23]. 
They used a binary cut off of 25 for the BMI in this 
study. We demonstrate, for the first time, using the WHO 
specified BMI groups, that an overweight and obese (I) 
BMI is prognostic of poor OS and may be predictive of 
a lack of response to VEGF- TT within a large multicenter 
database.
In contrast to our results, Simkens et al. demonstrate 
that BMI is an independent prognostic indicator of sur-
vival for patients receiving chemotherapy but not for those 
receiving chemotherapy and bevacizumab [11]. However, 
the overweight and obese patients included in their studies 
demonstrated a better performance status than those in 
the normal weight group, as their patient population was 
derived from a clinical trial database with a performance 
status of less than or equal to 2 as an inclusion criteria. 
The authors comment that this discrepancy may well have 
affected the results presented. However, our database is 
more likely to be more representative of the general popu-
lation as it is inclusive of patients both on clinical trials 
and off study. One other retrospective study has demon-
strated no association between BMI and either TTP or 
OS for mCRC patients treated with bevacizumab, but 
this was a small study of only 184 patients from a single 
center [24].
One major limitation of our study is that it was ret-
rospective in nature, as are the other studies examining 
the association of BMI and outcome for patients with 
mCRC in the literature [11, 12]. Furthermore, our results 
do not account for a potential variable distribution of 
VEGF- TT in adipose tissue, which may account for the 
reduced efficacy of these drugs in the overweight popula-
tion. One hypothesis for poorer outcomes in overweight 
or obese patients relates to dose capping of chemotherapy 
in these individuals [25, 26] which may be an important 
confounding factor within our study. Although we could 
not obtain exact chemotherapy doses for all patients, we 
have tried to control for this factor by comparing OS by 
BMI within the group of patients treated with chemo-
therapy alone. There are no significant differences in OS 
between normal, overweight, and obese patients treated 
with chemotherapy alone (21, 21.1, and 22 months, 
 respectively, Fig. 2, panel B). Therefore, we have concluded 
that inadequate chemotherapy dosing is unlikely to be a 
confounding factor for our results.
Prospective studies are now required to examine the 
pharmacokinetics and pharmacodynamics of such TT in 
overweight patients, as well as to gather data on cardio-
vascular comorbidities, smoking, and drug histories, in 
order to validate these results.
In conclusion, we found that BMI is an independent 
prognostic indicator of a poor OS for patients who are 
overweight and obese I, specifically for patients receiving 
chemotherapy and VEGF- TT. Patients within these groups 
may represent a target group for lifestyle and nutritional 
advice in order to improve OS with TT. Feasibility studies 
have demonstrated an improvement in health- related qual-
ity of life, symptoms, dietary habits, and BMI in CRC 
patients in the adjuvant setting with a relatively low cost 
technique, such as a telephone- delivered health behavior 
intervention [27, 28]. Further studies are required to in-
vestigate if such interventions are effective, both at reducing 
BMI and improving outcome for patients with mCRC.
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